Displaying 69 out of 979 Biotech companies
 Filter
City
Country
Stage
Business Model
Industry
Clear All
Export
Europe Biotech All business models
company score funding investors employees industries biz model city contact
Pheon Therapeutics HIRING

Antibody-Drug Conjugate specialist creating treatments for tough-to-treat cancers.
79
$120M · Series B TCG Crossover, Atlas Ventures, Brandon Capital 11 to 50 Health Tech, Biotech, Deep Tech, Pharma B2B London, UK •••••••••••@pheontx.com
SynOx Therapeutics HIRING

Developer of treatment for diffuse tenosynovial giant cell tumors.
68
$75M · Series B Bioqube Ventures, Medicxi, Forbion Capital Partners 1 to 10 Health Tech, Biotech B2B Dublin, Ireland •••••••••••@synoxtherapeutics.com
Tubulis

Developer of chemotherapeutic drugs designed to fight against cancer and chronic diseases.
68
$139M · Series B Nextech Invest, EQT Life Sciences, Andera Partners 11 to 50 Health Tech, Biotech, Deep Tech B2B Munich, Germany •••••••••••@tubulis.com
CN BioJUST ADDED HIRING

Provider of single and multi-organ microphysiological systems.
68
$21M · Series B CN Innovations 101 to 250 Health Tech, Biotech London, UK •••••••••••@cn-bio.com
ExpressionEditsJUST ADDED HIRING

AI-driven intronization technology developer.
68
$13M · Seed Octopus Ventures, Acequia Capital, Redalpine 1 to 10 AI, Biotech B2B, SaaS London, UK •••••••••••@expressionedits.com
Aqemia

Drug discovery platform.
64
$32M · Series A Wendel Growth, Bpifrance, Elaia 51 to 100 Biotech B2B Paris, France •••••••••••@aqemia.com
Causaly

Biomedical research discovery tool.
64
$60M · Series B ICONIQ Growth, Index Ventures, Pentech Ventures 51 to 100 Health Tech, AI, Biotech, Pharma B2B, SaaS London, UK •••••••••••@causaly.com
Beacon Therapeutics

Oophthalmic gene therapy company to treat blinding retinal illnesses.
64
$120M · Series A Syncona Partners LLP 1 to 10 Health Tech, Biotech London, UK •••••••••••@beacontx.com
Apollo Therapeutics

Portfolio of pharmaceutical research and discovery.
64
$33M · Series C Patient Square Capital, Rock Springs Capital, M&G Investments 1 to 10 Biotech, Pharma London, UK •••••••••••@apollotherapeutics.com
Eligo Bioscience

Gene-editing platform.
64
$30M · Series B Khosla Ventures, Sanofi Ventures, Bpifrance 11 to 50 Health Tech, Biotech Paris, France •••••••••••@eligo.bio
HEPHAISTOS-Pharma HIRING

Immunotherapies developer for cancer patient.
64
$4M · Seed Fournier-Majoie, France 2030, Elaia 1 to 10 Health Tech, Biotech Paris, France •••••••••••@hephaistos-pharma.fr
Bioptimus

Developer of a universal AI foundation model for biology.
64
$35M · Seed Frst, Bpifrance, Sofinnova Partners 1 to 10 AI, Biotech B2B, SaaS Paris, France •••••••••••@bioptimus.com
Cure51

Cancer survivors data analysis platform.
64
$16M · Seed Hitachi Ventures, Life Extension Ventures, Sofinnova Partners 11 to 50 Biotech, Data and Analytics B2B, SaaS Paris, France •••••••••••@cure51.com
Flindr TherapeuticsJUST ADDED HIRING

Precision oncology treatments developer.
64
$21M · Series A V-Bio Ventures 1 to 10 Health Tech, Biotech Amsterdam, Netherlands •••••••••••@flindrtx.com
Captain T CellJUST ADDED HIRING

Developer of next-generation T cells against solid tumors.
64
$9M · Seed Brandenburg Kapital, i&i Biotech Fund 1 to 10 Health Tech, Biotech Berlin, Germany •••••••••••@captaintcell.com
Adcendo HIRING

Antibody-drug conjugates (ADCs) developer for the treatment of cancer.
59
$17M · Series A RA Capital Management, Novo A/S, HealthCap 11 to 50 Health Tech, Biotech B2B Copenhagen, Denmark •••••••••••@adcendo.dk
Adionics

Eco-friendly liquid-liquid direct lithium extraction (DLE) process developer.
59
$27M · Series B Bpifrance, Celeste Management, Sociedad Quimica Y Minera (SQM) 11 to 50 Climate Tech & Green Tech, Biotech B2B Paris, France •••••••••••@adionics.com
Baseimmune

AI vaccine algorithm developer.
59
$11M · Series A Hoxton Ventures, Merck Global Health Innovation Fund, Cherry Ventures 1 to 10 AI, Biotech B2B, SaaS London, UK •••••••••••@baseimmune.co.uk
Mnemo Therapeutics

Biotechnology firm focused on life science advancements.
59
$89M · Series A Sofinnova Partners 101 to 250 Health Tech, Biotech B2B Paris, France •••••••••••@mnemo-tx.com
Onego Bio

Animal-free egg protein producer for food manufacturers.
59
$28M · Series A EIT Food, Agronomics, Tesi 11 to 50 Foodtech, Biotech B2B Helsinki, Finland •••••••••••@onego.bio
SparingVision

Biotechnology company focused on developing genomic medicines to treat blinding inherited retinal diseases.
59
$52M · Series A Ysios Capital 1 to 10 Health Tech, Biotech, Deep Tech B2B Paris, France •••••••••••@sparingvision.com
Vytrus Biotech HIRING

Active ingredient producer from plant stem cells for the cosmetics industry.
59
$2M · Seed Boyser SRL, ICF Capital 11 to 50 Biotech, Manufacturing B2B Barcelona, Spain •••••••••••@vytrus.com
Complement Therapeutics

Preclinical stage treatment for geographic atrophy.
59
$78M · Series A Forbion Capital Partners, Gimv 1 to 10 Biotech London, UK •••••••••••@complementtx.com
FA Bio

Discovery and development platform of superior microbial bioproducts.
59
$6M · Series A Pymwymic, Clean Growth Fund 1 to 10 Biotech London, UK •••••••••••@fungialert.com
Calluna Pharma

Developer of therapies for inflammatory and fibrotic diseases.
59
$81M · Series A Sarsia, p53, Forbion Capital Partners 11 to 50 Biotech, Pharma Oslo, Norway •••••••••••@callunapharma.com
IMU Biosciences

AI platform to map the human immune system.
59
$14M · Series A Molten Ventures, Life Extension Ventures 11 to 50 Health Tech, Biotech London, UK •••••••••••@imubiosciences.com
MIP Discovery

Developer of non-biological affinity reagents to accelerate the production of cell and gene therapies.
59
$8M · Series A Mercia Asset Management 11 to 50 Health Tech, Biotech London, UK •••••••••••@mipdiscovery.com
Stanhope AI

Neuroscience-driven AI platform.
59
$2M · Seed Rockmount Capital, Moonfire Ventures, UCL Technology Fund 11 to 50 AI, Biotech B2B, SaaS London, UK •••••••••••@stanhopeai.com
MetyosJUST ADDED

Biosensors developer to combat chronic kidney disease.
59
$2M · Pre Seed Bpifrance, Kima Ventures, Cenitz 1 to 10 Health Tech, Biotech Paris, France •••••••••••@metyos.com
NeurosterixJUST ADDED

Advanced allosteric modulator therapeutics developer for neurological disorders.
59
$63M · Series A Xontogeny, Perceptive Advisors, Acorn Bioventures 1 to 10 Health Tech, Biotech Geneva, Switzerland •••••••••••@neurosterix.com
Sparxell

Developer of sustainable plant-based pigments.
59
$3M · Seed PDS Ventures, Circular Innovation Fund, L'Oreal 1 to 10 Biotech, Manufacturing B2C London, UK •••••••••••@sparxell.com
En Carta DiagnosticsJUST ADDED HIRING

Point-of-care diagnostic platform.
59
$1M · Pre Seed CentraleSupélec Venture 1 to 10 Health Tech, Biotech Paris, France •••••••••••@encarta.bio
CatalYm HIRING

Innovative immunotherapies developer for cancer patients.
54
$150M · Series D Brandon Capital, Bioqube Ventures, Forbion Capital Partners 11 to 50 Health Tech, Biotech B2B Munich, Germany •••••••••••@catalym.com
Charm Therapeutics

Platform using deep learning on 3D molecular structures to develop treatments for harmful proteins.
54
$50M · Series A Khosla Ventures, General Catalyst 1 to 10 Health Tech, AI, Biotech, Data and Analytics B2B London, UK •••••••••••@charmtx.com
Egle Therapeutics

Biotechnology firm developing immunotherapies for cancer and autoimmune diseases.
54
$46M Bioqube Ventures 11 to 50 Health Tech, Biotech B2B Paris, France •••••••••••@egle-tx.com
Eyevensys

Platform that develops bio factories to treat significant eye diseases sustainably.
54
$30M · Series B Karista, Pureos Bioventures 11 to 50 Health Tech, Hardware, Biotech, Manufacturing B2B Paris, France •••••••••••@eyevensys.com
Lindus Health

Clinical trials platform.
54
$18M · Series A Valar Ventures, Creandum, Seedcamp 11 to 50 Health Tech, Biotech B2B, SaaS London, UK •••••••••••@lindushealth.com
MinervaX

Developer of prophylactic vaccine against Group B Streptococcus.
54
$57M · Series C EQT Partners, Novo A/S, OrbiMed 1 to 10 Health Tech, Biotech B2B Copenhagen, Denmark •••••••••••@minervax.com
Mytos

Fully-automated cell manufacturing.
54
$19M · Series A Buckley Ventures, Wing Venture Capital, IQ Capital Partners 11 to 50 Biotech, Machine Learning B2B London, UK •••••••••••@mytos.bio
Orbis Medicines

Oral macrocycle drug discovery platform.
54
$28M · Seed Novo A/S, Forbion Capital Partners 1 to 10 Health Tech, Biotech B2B Copenhagen, Denmark •••••••••••@orbismedicines.com
Ori Biotech

Manufacturing platform designed to help patients access lifesaving treatments.
54
$30M · Series A Kindred Capital, Octopus Ventures, Amadeus Capital 1 to 10 Health Tech, Biotech, Manufacturing B2B London, UK •••••••••••@oribiotech.com
Quell Therapeutics

Cell therapy firm specializing in developing treatments using advanced cellular technology.
54
$45M · Series A AlbionVC, Point72 Ventures 101 to 250 Health Tech, Edtech, Biotech, Manufacturing B2B London, UK •••••••••••@quell-tx.com
ReViral

Biotechnology firm developing antiviral treatments for patients.
54
$44M · Series C Novo A/S, Andera Partners 11 to 50 Health Tech, Biotech, Pharma B2B London, UK •••••••••••@reviral.co.uk
Tropic Biosciences

Platform specializing in developing new, high-yield tropical crop varieties and traits.
54
$28M · Series B Future Planet Capital 11 to 50 Agritech, Biotech, Deep Tech, Manufacturing B2B London, UK •••••••••••@tropicbioscience.com
Cultimate Foods HIRING

Fat ingredient producer for alternative meats.
54
$2M · Seed b.value AG, Life Science Valley Wachstumsfond, Kale United 1 to 10 Foodtech, Biotech B2B Berlin, Germany •••••••••••@cultimatefoods.com
Farmless

Fermentation process to produce protein from animals.
54
$5M · Seed Voyager Ventures, Revent, World Fund 1 to 10 Foodtech, Biotech B2C Amsterdam, Netherlands •••••••••••@farmless.com
AAVantgarde Bio

Gene therapies for inherited retinal disorders.
54
$65M · Series A Forbion Capital Partners 1 to 10 Biotech Milan, Italy •••••••••••@aavantgardebio.com
Astraveus

Automated bioprocessing system for the production of cell and gene therapies.
54
$18M · Seed AdBio Partners 11 to 50 Biotech Paris, France •••••••••••@astraveus.com
Umedeor

Platform to automate the clinical studies process.
54
$12M · Series A Playfair, Delin Ventures, 11.2 Capital 11 to 50 Health Tech, Biotech B2B London, UK •••••••••••@umed.io
Flarin

Patent-protected anti-inflammatory painkiller.
54
$6M · Series A ITV AdVentures 1 to 10 Biotech, Pharma B2C London, UK •••••••••••@flarin.co.uk
Genomes

User-owned genomics database platform.
54
$20M · Series A GEM Digital 1 to 10 Health Tech, Biotech B2C London, UK •••••••••••@genomes.io
Gradient Denervation Technologies

Medical devices for a transvascular treatment of pulmonary hypertension.
54
$14M · Series A Sofinnova Partners, Asabys Partners 1 to 10 Health Tech, Biotech Paris, France •••••••••••@gradientdenervation.com
Laverock Therapeutics

Gene silencing platform for the creation of programmable, allogeneic cell therapies.
54
$16M · Seed Mercia Asset Management, Calculus Capital, UK Innovation & Science Seed Fund 1 to 10 Health Tech, Biotech London, UK •••••••••••@laverocktx.com
Samabriva

Biomanufacturer of complex molecules.
54
$4M · Seed Meusinvest (Noshaq) 1 to 10 Biotech, Manufacturing Paris, France •••••••••••@samabriva.com
Hoba Therapeutics

Therapeutic protein developer for chronic neuropathic pain.
54
$24M · Series A Medical Incubator Japan, Borean Innovation, Novo A/S 1 to 10 Health Tech, Biotech Copenhagen, Denmark •••••••••••@hobatherapeutics.com
Vico Therapeutics HIRING

Medicine for rare neurological diseases.
54
$58M · Series B Droia Ventures, Ackermans & van Haaren, Idinvest Partners 11 to 50 Health Tech, Biotech B2C The Hague, Netherlands •••••••••••@vicotx.com
Paques Biomaterials

Polyhydroxyalkanoates (PHA) producer.
54
$15M · Seed NV NOM, Invest-NL 1 to 10 Biotech Amsterdam, Netherlands •••••••••••@paquesbiomaterials.nl
Quantistry

Cloud-native chemical simulation platform.
54
$3M · Seed Chemovator, Ananda Impact Ventures, IBB Ventures 11 to 50 Biotech, Cloud B2B, SaaS Berlin, Germany •••••••••••@quantistry.com
Hexigone InhibitorsJUST ADDED HIRING

Sustainable corrosion inhibitors manufacturer.
54
$1M · Seed Oxford Innovation Finance, Waterspring Ventures, Development Bank of Wales 1 to 10 Biotech, Manufacturing B2B London, UK •••••••••••@hexigone.com
LimulaJUST ADDED HIRING

Gene therapy platform.
54
$6M · Seed Life Extension Ventures, Zühlke Group, Oxford Seed Fund 1 to 10 Health Tech, Biotech Geneva, Switzerland •••••••••••@limula.ch
Nouscom

Viral vector-based cancer vaccines developer.
51
$82M · Series C Bpifrance, 5AM Ventures, Abingworth 1 to 10 Health Tech, Biotech B2C Basel, Switzerland •••••••••••@nouscom.com
Achilles Therapeutics

Immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer.
50
$17M · Seed AlbionVC, Boxer Capital, Syncona Partners LLP 101 to 250 Health Tech, Biotech B2B London, UK •••••••••••@achillestx.com
ADmit Therapeutics

Early detection of Alzheimer's disease (AD) technology.
50
$5M · Series A WA4STEAM, EIC Accelerator, Ship2B 1 to 10 Health Tech, Biotech, Pharma B2B Barcelona, Spain •••••••••••@admit-therapeutics.com
AMSilk

Developer of bio-fabricated silk protein materials.
50
$27M · Series C Novo A/S 11 to 50 Health Tech, Biotech, Manufacturing B2B Munich, Germany •••••••••••@amsilk.com
Ariceum Therapeutics

Diagnosis and treatment of hard-to-treat cancers.
50
$24M · Series A Earlybird Venture Capital, Andera Partners, HealthCap 11 to 50 Health Tech, Biotech, Pharma B2B Berlin, Germany •••••••••••@ariceum-therapeutics.com
Bactolife

Producer of gut health binding proteins.
50
$32M · Series A Bill & Melinda Gates Foundation, Novo A/S 1 to 10 Biotech, Pharma B2B Copenhagen, Denmark •••••••••••@bactolife.com
Daye

Gynecological health company creating products and services for vaginal treatment.
50
$5M · Seed Khosla Ventures, Index Ventures, Kindred Capital 11 to 50 Health Tech, Biotech, Manufacturing, Ecommerce, Cannabis B2C London, UK •••••••••••@yourdaye.com
EnginZyme

Bio alternative to fossil-based and energy–intensive chemical production.
50
$22M · Series B Sofinnova Partners, SEB Venture Capital, Industrifonden 51 to 100 Health Tech, Biotech B2B Stockholm, Sweden •••••••••••@enginzyme.com
Enterome

Cutting-edge immunomodulatory drugs for the treatment of cancer and immune diseases.
50
$3M · Series F The Leukemia & Lymphoma Society’s Therapy Acceleration Program, Omnes Capital, Nestlé Health Science 51 to 100 Health Tech, Biotech, Deep Tech, Pharma B2B Paris, France •••••••••••@enterome.com
OTHER INDUSTRIES
Other Biotech startups by location